| In millions, except per share items | Sep-30-11 | Sep-30-10 | Sep-30-09 | Sep-30-08 | Sep-30-07 | Sep-30-06 | Sep-30-05 | Sep-30-04 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| Revenues: |
| Diagnostic & Biopharmaceutical Products | 32.2 | 34.1 | 32.9 | 35.0 | 35.0 | 37.8 | | |
| BioServices | 11.3 | 16.2 | 11.6 | 14.0 | 12.3 | 11.4 | | |
| Diagnostic Products | | | | | | | | 17.5 |
| Other | | | | | | | | 10.9 |
| Total revenues | 43.5 | 50.4 | 44.4 | 49.0 | 47.3 | 49.2 | 50.3 | 28.4 |
| Revenue growth [+] | -13.7% | 13.4% | -9.3% | 3.5% | -3.8% | -2.2% | 76.9% | 22.6% |
| Diagnostic & Biopharmaceutical Products | -5.7% | 3.9% | -6.1% | 0.0% | -7.4% | | | |
| BioServices | -30.5% | 40.3% | -17.2% | 13.6% | 8.2% | | | |
| Diagnostic Products | | | | | | | | 75.0% |
| Cost of goods sold | 26.7 | 29.6 | 29.0 | 33.9 | 33.9 | 32.6 | 50.8 | 17.7 |
| Gross profit | 16.7 | 20.8 | 15.4 | 15.0 | 13.4 | 16.6 | -0.5 | 10.7 |
| Gross margin | 38.5% | 41.3% | 34.8% | 30.7% | 28.3% | 33.8% | -1.0% | 37.8% |
| Selling, general and administrative | 12.3 | 12.7 | 13.7 | 16.1 | 14.5 | 13.3 | 12.0 | 5.1 |
| Research and development | 1.3 | 0.8 | 1.1 | 1.8 | 0.6 | 0.5 | 0.4 | |
| Other operating expenses | 0.6 | 0.5 | 0.6 | | | | | |
| EBITDA [+] | 3.8 | 7.9 | 1.2 | -1.6 | -0.3 | 4.8 | -10.6 | 6.0 |
| EBITDA growth | -51.7% | 547.2% | -178.4% | 372.6% | -106.9% | -145.4% | -275.4% | 98.5% |
| EBITDA margin | 8.8% | 15.7% | 2.8% | -3.2% | -0.7% | 9.8% | -21.0% | 21.2% |
| Depreciation and amortization | 1.2 | 1.1 | 1.3 | 1.3 | 1.4 | 2.0 | 2.3 | 0.4 |
| EBIT [+] | 2.6 | 6.8 | 0.0 | -2.9 | -1.7 | 2.8 | -12.9 | 5.6 |
| EBIT growth | -62.2% | -16486.9% | -98.5% | 67.1% | -161.0% | -121.9% | -327.7% | 95.0% |
| EBIT margin | 6.0% | 13.6% | -0.1% | -5.9% | -3.6% | 5.7% | -25.6% | 19.8% |
| Non-recurring items [+] | | | 15.1 | 9.3 | 10.4 | 9.4 | | |
| Asset impairment | | | 15.1 | 8.0 | 5.2 | | | |
| Interest expense | 0.1 | 0.2 | 0.4 | 0.4 | 0.7 | 2.1 | 1.8 | 0.0 |
| Interest expense | 0.1 | 0.2 | 0.4 | 0.4 | 0.7 | 2.1 | 1.8 | 0.0 |
| Other income (expense), net [+] | 0.0 | 0.1 | 0.2 | 0.2 | -0.1 | -0.2 | -0.6 | -0.2 |
| Reorganization items | -0.8 | | | | | | | |
| Other | 0.0 | 0.1 | 0.2 | | | | | |
| Pre-tax income | 2.6 | 6.7 | -15.3 | -12.3 | -13.0 | -8.9 | -15.2 | 5.4 |
| Income taxes | -0.1 | 0.0 | 0.0 | -0.4 | 0.1 | 0.0 | -0.5 | 1.2 |
| Tax rate | | 0.1% | | 3.0% | | 0.3% | 3.4% | 23.0% |
| Earnings from continuing ops | 2.7 | 6.7 | -15.4 | -12.0 | -13.1 | -8.9 | -14.7 | 4.2 |
| Earnings from discontinued ops | | | | | -0.1 | -15.4 | -6.4 | |
| Net income | 2.7 | 6.7 | -15.4 | -12.0 | -13.2 | -24.3 | -21.1 | 4.2 |
| Net margin | 6.1% | 13.3% | -34.6% | -24.4% | -27.8% | -49.4% | -41.9% | 14.6% |
| |
| Basic EPS [+] | $0.14 | $0.36 | ($0.83) | ($0.64) | ($0.82) | ($0.63) | ($1.32) | $0.51 |
| Growth | -60.5% | -143.1% | 28.3% | -21.6% | 29.6% | -52.0% | -360.4% | 45.4% |
| Diluted EPS [+] | $0.14 | $0.35 | ($0.83) | ($0.64) | ($0.82) | ($0.63) | ($1.32) | $0.45 |
| Growth | -60.6% | -142.4% | 28.3% | -21.6% | 29.6% | -52.0% | -397.2% | 41.6% |
| |
| Shares outstanding (basic) [+] | 18.9 | 18.8 | 18.6 | 18.6 | 15.9 | 14.0 | 11.1 | 8.2 |
| Growth | 0.6% | 1.2% | 0.2% | 16.9% | 13.5% | 26.0% | 35.8% | 9.2% |
| Shares outstanding (diluted) [+] | 19.3 | 19.1 | 18.6 | 18.6 | 15.9 | 14.0 | 11.1 | 9.3 |
| Growth | 1.0% | 2.7% | 0.2% | 16.9% | 13.5% | 26.0% | 18.9% | 12.2% |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |